ENVB NASDAQ
Enveric Biosciences, Inc.
1W: -1.3%
1M: +2.8%
3M: +0.0%
YTD: -59.7%
1Y: -81.4%
3Y: -99.6%
5Y: -100.0%
$1.48
+0.02 (+1.37%)
Weekly Expected Move ±6.4%
$1
$1
$1
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
7 relationships7
As Filer
counterparties named
0
As Counterparty
mentioned by others
4
Rel. Types
2022-02-15
Earliest Filing
2024-11-12
Latest Filing
partner: 4
licensee: 1
target: 1
acquirer: 1
Counterparties (Filed by ENVB)
7 relationshipsCompanies named in ENVB's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| MycoMedica Life Sciences | — | licensee | Out-licensed Enveric's EB-002 drug candidate for development and commercialization in neuropsychiatric disorders. | 2024-11-12 | View |
| Enveric Biosciences | ENVB | partner | Licensed radiation dermatitis product to Aries for clinical development and marketing | 2024-07-15 | View |
| Aries Science & Technology | — | partner | Licensed radiation dermatitis product from Enveric for clinical development and marketing | 2024-07-15 | View |
| Akos Biosciences, Inc. | — | partner | Enveric's subsidiary through which the licensing agreement was executed | 2024-07-15 | View |
| Canaccord Genuity LLC | — | partner | Sales agent and/or principal for the equity distribution agreement. | 2023-09-01 | View |
| Enveric BioSciences, Inc. | ENVB | target | Company issuing securities in an underwriting agreement | 2022-02-15 | View |
| A.G.P./Alliance Global Partners | — | acquirer | Representative of the several underwriters purchasing securities | 2022-02-15 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-14 | Earnings Release; Exhibits | View | |
| 2026-06-09 | Regulation FD; Exhibits | View | |
| 2026-06-09 | Other Events; Exhibits | View | |
| 2026-05-29 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-05-15 | Earnings Release; Exhibits | View | |
| 2026-04-20 | Material Agreement; Unregistered Equity Sales; Other Events; Exhibits | Agreement | View |
| 2026-03-27 | Earnings Release; Exhibits | View | |
| 2026-02-06 | Other Events; Financial Statements and Exhibits | View | |
| 2026-01-28 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Financial Stateme | Agreement | View |
| 2026-01-09 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-12-12 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Financial Stateme | Agreement | View |
| 2025-12-11 | Submission of Matters to a Vote of Security Holders; Financial Statements and Exhibits | View | |
| 2025-11-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-14 | Other Events | View | |
| 2025-10-23 | Notice of Delisting or Transfer; Material Modification to Rights of Security Holders; Amendments to | View | |
| 2025-09-18 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Financial Stateme | Agreement | View |
| 2025-09-02 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-08-29 | Notice of Delisting or Transfer | View | |
| 2025-08-29 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-08-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR